Entrada Therapeutics Income Statement (2020-2026) | TRDA

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
25.26M18.17M43.73M41.85M59.12M94.69M19.57M37.40M20.56M1.95M1.61M1.30M0.88M
Operating items
Research & Development (Quarter)
6.83M10.51M12.36M15.72M16.25M18.96M15.69M23.10M26.30M22.19M28.29M28.61M32.03M31.26M33.41M32.07M37.88M38.36M33.96M33.05M
Selling, General & Administrative (Quarter)
3.08M3.85M6.10M6.43M7.33M6.98M9.89M7.94M8.17M7.53M8.65M9.40M9.24M9.97M9.86M10.27M10.92M10.30M9.55M10.12M
Operating Expenses (Quarter)
9.91M14.36M18.46M22.15M23.58M25.94M25.58M31.04M34.47M29.72M36.94M38.01M41.27M41.23M43.27M42.35M48.80M48.66M43.51M43.18M
Operating Income (Quarter)
-9.91M-14.36M-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M
EBIT (Quarter)
-9.91M-14.36M-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M
Non-operating items
Interest & Investment Income (Quarter)
0.01M-0.07M0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M
Other Non Operating Income (Quarter)
0.01M-0.07M0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M
Non Operating Income (Quarter)
0.01M-0.07M0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M
Net income details
EBT (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-3.12M-12.08M18.06M9.24M25.33M57.79M-15.89M-0.74M-17.35M-42.92M-43.48M-39.07M-39.68M
Tax Provisions (Quarter)
3.55M13.85M-17.40M18.70M1.83M2.80M-1.90M-1.80M0.20M0.70M0.12M0.04M
Profit After Tax (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.54M23.50M55.03M-14.03M1.13M-17.35M-43.10M-44.13M-39.16M-39.72M
Income from Continuing Operations (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.46M23.50M54.99M-13.99M1.06M-17.35M-43.12M-44.18M-39.20M-39.72M
Consolidated Net Income (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.46M23.50M54.99M-13.99M1.06M-17.35M-43.12M-44.18M-39.20M-39.72M
Income towards Parent Company (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.46M23.50M54.99M-13.99M1.06M-17.35M-43.12M-44.18M-39.20M-39.72M
Net Income towards Common Stockholders (Quarter)
-9.90M-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.46M23.50M54.99M-13.99M1.06M-17.35M-43.12M-44.18M-39.20M-39.72M
Additional items
EPS (Basic) (Quarter)
-7.56-9.7816.02-0.69-0.74-0.80-0.78-0.21-0.781.07-0.290.701.61-0.35-0.03-0.42-1.04-1.06-0.94-0.95
EPS (Weighted Average and Diluted) (Quarter)
-7.56-9.7816.02-0.69-0.74-0.80-0.78-0.21-0.781.02-0.280.681.55-0.35-0.04-0.42-1.04-1.06-0.94-0.95
Shares Outstanding (Weighted Average) (Quarter)
1.29M1.35M6.27M31.25M31.28M31.30M31.29M32.37M33.16M32.94M33.05M33.50M33.84M36.12M37.31M41.07M41.34M41.46M41.37M41.84M
Shares Outstanding (Diluted Average) (Quarter)
1.29M1.35M6.27M31.25M31.26M31.27M31.29M32.37M32.77M34.78M33.05M34.79M35.15M37.58M39.00M41.07M41.34M41.29M41.37M41.84M
EBITDA (Quarter)
-9.90M-14.43M-18.45M-23.21M-23.91M-25.62M-23.94M-5.26M-26.29M35.97M-8.85M23.05M54.95M-12.73M0.12M-16.87M-43.14M-43.91M-39.13M-40.12M
Shares Outstanding (Quarter)
1.41M1.55M31.22M31.26M31.28M31.33M31.39M33.13M33.21M33.34M33.44M33.60M37.17M37.40M37.57M37.94M38.03M38.22M38.28M38.82M
Tax Rate (Quarter)
-113.70-114.62-96.33202.367.234.8511.96243.57-0.47-1.61-0.32-0.10